The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases

Teresa R Kee1,2, Sophia A Khan1, Maya B Neidhart1

  • 1Department of Pathology, CWRU School of Medicine, Cleveland, OH, 44106, USA.

PubMed

Insights

Beta-arrestins are key proteins in cell signaling that also play critical roles in neurodegenerative diseases like Alzheimer's, Parkinson's, and frontotemporal dementia. Targeting beta-arrestins may offer new therapeutic strategies for these conditions.

Area of Science:

  • Molecular and Cellular Biology
  • Neuroscience
  • Biochemistry

Background:

  • Arrestins are crucial regulators of G-protein-coupled receptor (GPCR) pathways, involved in desensitization, signaling, and internalization.
  • Beyond GPCRs, beta-arrestins function as scaffolds and adapters, interacting with various cellular components and non-GPCR receptors.

Purpose of the Study:

  • To review the physiological functions of beta-arrestin1 and beta-arrestin2.
  • To elucidate the involvement of beta-arrestins in the pathogenesis of neurodegenerative diseases.

Main Methods:

  • Literature review of recent studies on beta-arrestin function and neurodegeneration.
  • Analysis of molecular mechanisms linking beta-arrestins to Alzheimer's, Parkinson's, and frontotemporal dementia.

Main Results:

  • Beta-arrestins interact with gamma-secretase, increasing amyloid-beta production in Alzheimer's disease.
  • Beta-arrestin oligomers impair autophagy by inhibiting p62/SQSTM1, leading to tau pathology in frontotemporal dementia.
  • Upregulation of beta-arrestins and regulation of SNCA gene expression by beta2AR are observed in Parkinson's disease models.

Conclusions:

  • Beta-arrestins exhibit multifaceted roles extending beyond GPCR regulation.
  • The significant involvement of beta-arrestins in neurodegenerative diseases highlights their potential as therapeutic targets.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
806
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.5K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
609